Difference between revisions of "Colorectal cancer, KRAS-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
||
| Line 4: | Line 4: | ||
</div> | </div> | ||
{{#lst:Section editor transclusions|gi}} | {{#lst:Section editor transclusions|gi}} | ||
| − | <big>Note: the page has regimens specific to BRAF-mutated colon cancer. | + | <big>Note: the page has regimens specific to BRAF-mutated colon cancer. |
*See the [[Colorectal_cancer|'''main colorectal cancer page''']] for general regimens.</big> | *See the [[Colorectal_cancer|'''main colorectal cancer page''']] for general regimens.</big> | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
Revision as of 01:52, 1 June 2023
Section editor transclusions Note: the page has regimens specific to BRAF-mutated colon cancer.
- See the main colorectal cancer page for general regimens.
5 regimens on this page
8 variants on this page
|
Advanced or metastatic disease, subsequent lines of therapy
Adagrasib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Yaeger et al. 2022 (KRYSTAL-1) | NR in abstract | Phase 1/2 |
Biomarker eligibility criteria
- KRAS p.G12C mutation
References
- KRYSTAL-1: Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. Epub 2022 Dec 21. link to original article contains dosing details in abstract link to PMC article PubMed Clinical Trial Registry
Adagrasib & Cetuximab
Regimen variant #1
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Yaeger et al. 2022 (KRYSTAL-1) | NR in abstract | Phase 1/2 |
Biomarker eligibility criteria
- KRAS p.G12C mutation
Targeted therapy
- Adagrasib (Krazati) 600 mg PO twice per day
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg IV once on day 1
- Cycle 2 onwards: 250 mg IV once on day 1
7-day cycles
Regimen variant #2
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Yaeger et al. 2022 (KRYSTAL-1) | NR in abstract | Phase 1/2 |
Biomarker eligibility criteria
- KRAS p.G12C mutation
Targeted therapy
- Adagrasib (Krazati) 600 mg PO twice per day
- Cetuximab (Erbitux) 500 mg IV once on day 1
14-day cycles
References
- KRYSTAL-1: Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. Epub 2022 Dec 21. link to original article contains dosing details in abstract link to PMC article PubMed Clinical Trial Registry